secwatch.observer — SEC 8-K summary
======================================

Issuer:     Niagen Bioscience, Inc. (NAGE)
CIK:        0001386570
Form:       8-K
Filed at:   2022-08-10T23:59:59+00:00
Accession:  0001851734-22-000422
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ChromaDex Q2 net sales $16.7M (-5% YoY); CFO Farr terminated, Gerber interim CFO
--------------------------------------------------------------------------------

- Net sales $16.7M, down 5% YoY; Tru Niagen sales $14.5M (-6%). Gross margin 60%. Net loss $6.4M ($0.09 loss per share).
- CFO Kevin Farr terminated without cause on Aug 10, eff. Aug 12; Brianna Gerber appointed SVP Finance/Interim CFO.
- Hamed Shahbazi (CEO of WELL Health) appointed to Board, eff. Aug 9, joins Nominating and Corp Gov committee.
- Farr receives separation: 89,189 RSUs, $30,442 lump sum, accelerated equity vesting, pro-rata bonus, 90-day consulting.
- Company plans to reduce brand campaigns in H2 2022, shift focus to e-commerce and expense management.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1386570/000185173422000422/0001851734-22-000422-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1386570/000185173422000422/cdxc20220809_8k.htm
  HTML page:      https://secwatch.observer/filing/0001851734-22-000422

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer